Funding Details
- Awarder
- PlugAndPlayTechCenter
- Date Award
- May 15, 2024
- Funding URL
- View Funding Page
Company Info
- Company Description
- At Quibim, our ambition is to turn medical imaging into a catalyst for precision health. We design pioneering tools that unlock imaging data to improve patient outcomes and maximize the value of drug development & commercialization programs. Quibim offers a comprehensive approach that provides an all-in-one environment for all imaging-related needs, from data collection to prediction. Utilizing state-of-the-art imaging processing and artificial intelligence algorithms, Quibim's products extract more precise and clinically relevant information, enabling accurate patient endpoint estimations. As a foundational product focus, we develop and commercialize organ-specific AI products (e.g., QP-Liver®), classified as medical devices for regulatory purposes, to enhance radiology workflows for clinics and hospitals. Our most advanced device is QP-Prostate®, which optimizes clinical workflow and supports accurate decision-making for prostate MRI exams. QP-Prostate is currently FDA 510(k), UKCA, and CE mark cleared for automated prostate segmentation (prostate size & volume). QP-Prostate® is on track to get FDA clearance for automated lesion detection during H1 2024. Our second most advanced product is QP-Brain®, which is pending FDA clearance for automatic brain volumetry white-mater-lesion (WML) detection. QP-Liver® is under development for accurate quantification of tissue fat and iron from MRI. Our next-gen product focus, which is Quibim’s emerging and differentiated capability, is centered on developing imaging biomarker panels based on radiomics and AI technologies. We achieve this by partnering with biopharmaceutical and real-world-evidence (RWE) companies to develop medical imaging-based drug development tools and companion diagnostics that correspond to specific therapeutic programs.
Links